Skip to content
All Podcasts – Lifestyle
Author:
Sanofi Winthrop Industrie
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
March 24, 2026
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
March 18, 2026
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
March 6, 2026
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
March 6, 2026
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
March 5, 2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
March 5, 2026
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
March 5, 2026
←
Previous Page
1
2
3